Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
Fortress Biotech (Nasdaq: FBIO) announced that Lindsay A. Rosenwald, M.D., Chairman, President and CEO, will participate in a fireside chat at the H.C.
Rhea-AI Summary
Fortress Biotech (Nasdaq: FBIO) announced that Lindsay A. Rosenwald, M.D., Chairman, President and CEO, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026 at 12:30pm ET.
According to Fortress Biotech, the session is virtual and registration is available via the conference website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – FBIO
On May 4, the day this news came out, FBIO closed 2.15% above the previous close.
Data tracked by StockTitan Argus for the May 4 session.
Key Figures
- Conference date
- May 6, 2026
- H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
- Event time
- 12:30 pm ET
- Scheduled start of Fortress fireside chat
- Conference edition
- 2nd annual
- H.C. Wainwright Royalty Company Virtual Conference
Historical Context
-
Journey Medical expanded Emrosi payer access to over 150 million lives.
-
Fortress reported 2025 results with FDA approval and major asset monetizations.
-
Cyprium closed $205M PRV sale; Fortress expected over $100M proceeds.
-
Journey Medical posted higher 2025 revenues, better margins and narrowed loss.
-
Journey Medical scheduled its year-end 2025 earnings release and webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, taking place on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 12:30pm ET.
To register for the conference, visit https://hcwevents.com/royalty-company-conference.
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Center and Sentynl Therapeutics. For more information, visit www.fortressbiotech.com.
Company Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.